Glutamate receptor ionotropic AMPA type subunit 1 (GluA1)

Glutamate receptor ionotropic AMPA type subunit 1 (GluA1) is a protein that forms part of the AMPA subtype of ionotropic glutamate receptors, which are essential mediators of fast excitatory neurotransmission in the mammalian central nervous system. The functional receptor is typically a tetramer composed either entirely or partially from four related subunits—GluA1 through GluA4—encoded by separate genes (GRIA1-GRIA4)[4]. Most native receptors are heterotetramers containing both GluA2 and one other subunit such as GluA1. The structure includes an extracellular amino-terminal domain involved in assembly and trafficking, a ligand-binding domain that binds L-glutamate, and transmembrane domains forming an ion-conducting pore selective primarily for sodium ions but also permeable to calcium under certain conditions depending on composition. The M2 loop within each subunit forms part of the selectivity filter within the pore.[4] GluA1-containing AMPARs play critical roles not only in baseline synaptic transmission but also in activity-dependent processes such as long-term potentiation—a cellular correlate for learning and memory—and are implicated in various neurological diseases when their function is disrupted.[3][5] Dysfunctional regulation or mutations affecting these receptors have been linked to neurodegeneration, epilepsy, psychiatric disorders, and cognitive deficits. AMPARs including those containing GluA1 can be targeted pharmacologically by noncompetitive antagonists like perampanel; however, most available drugs do not distinguish between different AMPAR subunits. Modulation must be approached cautiously due to risks associated with altering fundamental CNS signaling pathways.[6]

Other names

GluR1GRIA1 (gene name)AMPA receptor subunit GluA1Ionotropic glutamate receptor 1[4][6]

For drugs targeting this molecule/receptor class: Noncompetitive antagonism of ligand-gated cation channels to reduce excitatory neurotransmission. Some agents act as positive allosteric modulators to enhance function; others as negative allosteric modulators or direct antagonists.